After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ESO-T01 delivers its first four multiple myeloma case reports.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
